在家族性高脂血症和隔离心脏移植中使用Evolocumab
Colin Mackenzie1, McHale Anderson2, Kevin S Shah2
1Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
JACC. Case reports
|August 19, 2024
概括
在家族性高脂血症患者的心脏移植后,Evolocumab有效控制了脂质. 这一案例突显了蛋白转化酶素素9抑制剂在移植后护理和器官分配策略中的潜力.
科学领域:
- 心脏病学 心脏病学
- 移植医学 移植医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 家庭性高脂血症对心血管健康构成挑战.
- 心脏移植需要仔细的术后管理,包括脂质控制.
- 蛋白转化酶亚素素9 (PCSK9) 抑制剂提供了一种新的治疗途径.
研究的目的:
- 报告一种新的evolocumab用于心脏移植后的脂质管理.
- 在一个独特的移植场景中评估PCSK9抑制剂的疗效.
- 讨论对器官分配和移植等待名单时间的影响.
主要方法:
- 一个病例研究,一个患有家族性高脂血症的患者接受了心脏移植.
- 给药和监测evolocumab用于术后脂质控制.
- 临床结果和脂质资料的分析.
主要成果:
- 在移植后使用evolocumab成功实现脂质控制.
- 患者对PCSK9抑制剂的良好的耐受性和临床反应.
- 在移植后立即使用PCSK9抑制剂的可行性.
结论:
- 埃沃洛库马布是心脏移植患者高脂血症管理的可行选择.
- 这一案例凸显了PCSK9抑制剂在复杂移植病例中的潜在益处.
- 结果可能会为未来的器官分配策略提供信息,并减少移植等候名单的持续时间.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
604
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
604
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Blood Studies for Cardiovascular System III: Serum Lipid Profile
141
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
141
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
145
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
145


